6zs8
From Proteopedia
(Difference between revisions)
| (3 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==X-ray structure of the adduct formed upon treating lysozyme with an aged solution of arsenoplatin-1== | |
| + | <StructureSection load='6zs8' size='340' side='right'caption='[[6zs8]], [[Resolution|resolution]] 2.15Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6ZS8 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6ZS8 FirstGlance]. <br> | ||
| + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.153Å</td></tr> | ||
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=A6R:arsenoplatin-1'>A6R</scene>, <scene name='pdbligand=DMS:DIMETHYL+SULFOXIDE'>DMS</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=NO3:NITRATE+ION'>NO3</scene></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6zs8 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6zs8 OCA], [https://pdbe.org/6zs8 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6zs8 RCSB], [https://www.ebi.ac.uk/pdbsum/6zs8 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6zs8 ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Arsenoplatin-1 (AP-1) is an innovative dual-action anticancer agent that contains a platinum(ii) center coordinated to an arsenous acid moiety. We found that AP-1 spontaneously aggregates in aqueous solutions generating oligomeric species of increasing length. Afterward, we succeeded in solving the crystal structure of the adduct formed between the model protein lysozyme and an early AP-1 oligomer that turned out to be a trimer. Remarkably, this crystal structure traps an early stage of AP-1 aggregation offering detailed insight into the molecular process of the oligomer's growth. | ||
| - | + | The first step of arsenoplatin-1 aggregation in solution unveiled by solving the crystal structure of its protein adduct.,Ferraro G, Cirri D, Marzo T, Pratesi A, Messori L, Merlino A Dalton Trans. 2020 Dec 15. doi: 10.1039/d0dt04068a. PMID:33320144<ref>PMID:33320144</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | [[Category: | + | </div> |
| - | [[Category: Ferraro | + | <div class="pdbe-citations 6zs8" style="background-color:#fffaf0;"></div> |
| - | [[Category: Merlino | + | |
| + | ==See Also== | ||
| + | *[[Lysozyme 3D structures|Lysozyme 3D structures]] | ||
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Ferraro G]] | ||
| + | [[Category: Merlino A]] | ||
Current revision
X-ray structure of the adduct formed upon treating lysozyme with an aged solution of arsenoplatin-1
| |||||||||||
